Cowles spoke with ScienceBoard.net at the 2022 Biotechnology Innovation Organization (BIO) International Convention about EpiCypher's efforts to harness the power of chromatin science and provide insights into the chromatin regulatory system, which plays a critical role in many disease processes.
"What we do is we study and provide tools to let researchers get the regulation information off of chromatin," said Cowles, who noted that "30 percent of chromatin is regulatory" which can provide an "extra layer of information that we think can be predictive to stratify patients."
EpiCypher has two major business areas: biochemistry, which creates recombinant nucleosomes, and genomic mapping and chromatin profiling technologies. The company's technologies can be used for a number of applications including quantitative mapping of chromatin targets, high-throughput epigenomic profiling of clinical samples, and biochemical characterization of epigenetic targets for drug discovery and inhibitor development.
Watch the video below to learn more.